This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Earnings Preview: Curis (CRIS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of -9.09% and -1.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Curis (CRIS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for May 20th
by Zacks Equity Research
AXDX, CRIS, FSTR, GO, and PRLB have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2021
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.
Will Curis (CRIS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Curis (CRIS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curis (CRIS) Surges: Stock Moves 5% Higher
by Zacks Equity Research
Curis (CRIS) saw a big move last session, as its shares jumped 5% on the day, amid huge volumes.
Biotech Stock Roundup: ASH Data in Focus, CRIS, BCRX Surge & More Pipeline News
by Zacks Equity Research
Data readouts at ASH take centerstage in the biotech sector as Fate (FATE) and CRISPR (CRSP) among others provide key updates.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
Has Curis (CRIS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRIS) Outperforming Other Medical Stocks This Year?
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRIS) Outperforming Other Medical Stocks This Year?
Aduro BioTech (ADRO) Looks Good: Stock Adds 7.7% in Session
by Zacks Equity Research
Aduro BioTech (ADRO) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
New Strong Buy Stocks for December 13th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Curis (CRIS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex' (VRTX) third-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Curis (CRIS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Curis, Inc. (CRIS).
Curis (CRIS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 36.59% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Do Options Traders Know Something About Curis (CRIS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Curis (CRIS) stock based on the movements in the options market lately.